CABACabaletta Bio, Inc.

Nasdaq www.cabalettabio.com


$ 12.62 $ -0.07 (-0.55 %)    

Thursday, 16-May-2024 15:59:59 EDT
QQQ $ 451.64 $ -1.83 (-0.4 %)
DIA $ 399.14 $ -0.14 (-0.04 %)
SPY $ 528.49 $ -1.29 (-0.24 %)
TLT $ 92.06 $ -0.04 (-0.04 %)
GLD $ 220.06 $ -0.83 (-0.38 %)
$ 12.62
$ 12.55
$ 0.00 x 0
$ 0.00 x 0
$ 12.30 - $ 12.79
$ 9.02 - $ 26.35
1,105,172
na
612.63M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-01-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-03-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 12-05-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-30-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

 cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

 citigroup-maintains-buy-on-cabaletta-bio-raises-price-target-to-30

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $26 to...

 cabaletta-bio-issued-idnct06328777-for-phase-12-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-201-a-cd19-car-t-cell-therapy-in-subjects-with-systemic-sclerosis-posted-to-clinical-trials-website-on-2024-03-25-study-is-not-yet-recruiting

https://clinicaltrials.gov/study/NCT06328777   Inclusion Criteria:

 cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

 wells-fargo-maintains-overweight-on-cabaletta-bio-raises-price-target-to-35

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-cabaletta-bio-raises-price-target-to-30

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target fr...

 recap-cabaletta-bio-q4-earnings
Recap: Cabaletta Bio Q4 Earnings
03/21/2024 13:10:06

 cabaletta-bio-inc-files-for-mixed-shelf-offering-size-not-disclosed

- SEC Filing

 cabaletta-bio-q4-eps-046-misses-039-estimate-cabaletta-had-cash-cash-equivalents-and-short-term-investments-of-2412m-expected-to-fund-its-operating-plan-into-the-first-half-of-2026

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.3...

 cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF).

 jefferies-initiates-coverage-on-cabaletta-bio-with-buy-rating-announces-price-target-of-36

Jefferies analyst Kelly Shi initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target o...

 cabaletta-bio-gets-additional-fda-fast-track-designations-for-caba-201-in-dermatomyositis-and-systemic-sclerosis

To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION